Takeda Pharmaceutical Co Ltd executive Ramy Riad Ahmed, President of the PDT business unit, reported a sale of 7,277 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. A footnote states this was a mandatory sale to cover taxes related to the vesting of equity awards. Following this transaction, Ahmed directly holds 102,588 American Depositary Shares.
Takeda Pharmaceutical Co Ltd executive Rhonda Janice Pacheco, President, U.S. Business Unit, reported the sale of 16,901 American Depositary Shares on 2026-08-10. The transaction was a mandatory sale to cover taxes triggered by vesting of equity awards, executed at a $17.10 weighted average price per ADS. Following this tax-related sale, she directly holds 182,507 ADS.
TAKEDA PHARMACEUTICAL CO LTD executive Lauren Rusckowski Duprey, Chief Transformation Officer, reported selling 47,586 American Depositary Shares on 2026-08-10. The sale was described as a mandatory sale to cover taxes associated with vesting of equity awards. The reported $17.10 figure is a weighted average price for the transaction. After this sale, Duprey directly held 226,057 American Depositary Shares.
TAKEDA PHARMACEUTICAL CO LTD director and President, R&D Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, he holds 766,569 ADSs directly and 281,307 ADSs indirectly through a trust.
Takeda Pharmaceutical Co Ltd executive Marcello Pignagnoli, Head of Strategic & Portfolio Development, reported a sale of 22,957 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes associated with the vesting of equity awards. Following the transaction, Pignagnoli directly held 176,977 ADS.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of OBU, reported selling 50,012 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. A footnote states this was a mandatory sale to cover taxes on vesting equity awards. She now directly holds 252,010 ADS.
Takeda Pharmaceutical Co Ltd reports that executive Shannon Elaine Mary, President, Global Supply & Quality, sold 3,978 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The company notes this was a mandatory sale to cover taxes associated with vesting equity awards. After the transaction, Mary held 63,333 ADSs directly.
Takeda Pharmaceutical Co Ltd executive Gabriele Ricci, Chief Data & Tech. Officer, reported a sale of 25,088 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards, and Ricci now directly holds 171,654 ADSs.
Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling 6,774 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. After this sale, she directly holds 53,029 ADS.
Takeda Pharmaceutical Co Ltd President and CEO Julie So-Young Kim reported selling 89,090 American Depositary Shares on August 10, 2026 at a weighted average price of $17.10 per share. The company states this was a mandatory sale to cover taxes on vesting equity awards, leaving her with 391,489 ADS held directly.